- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01094964
Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer
HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Drugs used in chemotherapy, such as mitomycin C and epirubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as bacillus calmette-guerin (BCG) and interferon alfa, may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether giving hyperthermia together with mitomycin C is more effective than giving BCG or standard therapy as second-line therapy in treating patients with recurrent bladder cancer.
PURPOSE: This randomized phase III trial is studying how well hyperthermia given together with mitomycin C works compared with BCG or standard therapy as second-line therapy in treating patients with recurrent bladder cancer.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- To determine whether hyperthermia in combination with mitomycin C versus bacillus Calmette-Guerin (BCG) or standard therapy as second-line therapy is effective in patients with recurrent non-muscle invasive bladder cancer following induction or maintenance therapy with BCG.
- To compare disease-free survival time in all patients.
- To compare complete response rate at 3 months in patients with carcinoma in situ.
Secondary
- To compare progression-free survival, overall survival, safety and tolerability of treatments, quality of life, cost, and cost-effectiveness in these patients.
- To assess biomarkers of response to standard and investigational treatment.
OUTLINE: This is a multicenter study. Patients are stratified according to presence of carcinoma in situ (yes vs no), prior bacillus Calmette-Guérin (BCG) therapy (induction vs maintenance), and participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I (experimental): Patients receive intravesical mitomycin C over two 30-minute instillations per session, and bladder hyperthermia (42 +/-2°C) is delivered in combination with each instillation. The suspension is maintained in the bladder for up to 2 hours. Treatment repeats once a week for 6 weeks followed by a 6-week rest period. Patients who are disease-free proceed to maintenance therapy consisting of one instillation of mitomycin C with bladder hyperthermia every 6 weeks for 1 year and then once every 8 weeks for 1 year. Patients who are disease-free at 24 months may continue treatment at the discretion of the clinician.
Arm II (control): Patients receive 1 of the following treatment regimens depending on prior BCG treatment.
- Second course of BCG therapy (patients who failed previous induction BCG): Patients receive intravesical BCG (1 instillation) once a week for 6 weeks. The suspension is maintained in the bladder for up to 2 hours. Patients then receive maintenance therapy consisting of BCG once a week for 3 weeks in months 3, 6, 12, 18, and 24. Patients who are disease-free at 24 months may continue treatment at the discretion of the clinician.
- Standard therapy (patients who failed previous maintenance BCG): Patients receive standard therapy for BCG failure as defined by their treating centers. Standard therapy may include intravesical BCG alone, intravesical mitomycin C alone, intravesical epirubicin hydrochloride alone, or intravesical BCG in combination with interferon alpha.
All patients undergo cystoscopic surveillance with or without a biopsy every 3 months for 2 years. Urine, blood, and tissue samples are collected periodically for biomarker laboratory studies. Patients complete quality of life questionnaires (EORTC QLQ-BLS24, QLQ-C30, and EQ5D) at baseline, at 12 weeks, and at 6, 9, and 12 months.
After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months thereafter.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
England
-
Basingstoke, England, United Kingdom, RG24 9NA
- Recruiting
- Basingstoke and North Hampshire NHS Foundation Trust
-
Contact:
- Contact Person
- Phone Number: 44-1256-314-700
-
Birmingham, England, United Kingdom, B15 2TH
- Recruiting
- Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust
-
Contact:
- Contact Person
- Phone Number: 44-121-472-1311
-
Leeds, England, United Kingdom, LS9 7TF
- Recruiting
- Leeds Cancer Centre at St. James's University Hospital
-
Contact:
- Contact Person
- Phone Number: 44-113-243-3144
-
Leicester, England, United Kingdom, LE1 5WW
- Recruiting
- University Hospitals of Leicester NHS Trust
-
Contact:
- Contact Person
- Phone Number: 44-300-303-1573
-
London, England, United Kingdom, SW17 0QT
- Recruiting
- St. George's Hospital
-
Contact:
- Contact Person
- Phone Number: 44-208-672-1255
-
London, England, United Kingdom, WC1E 6AU
- Recruiting
- University College of London Hospitals
-
Contact:
- Contact Person
- Phone Number: 44-845-1555-000
-
Manchester, England, United Kingdom, M20 2LR
- Recruiting
- South Manchester University Hospital
-
Contact:
- Contact Person
- Phone Number: 44-161-998-7070
-
Middlesbrough, England, United Kingdom, TS19 8PE
- Recruiting
- James Cook University Hospital
-
Contact:
- Contact Person
- Phone Number: 44-1609-779-911
-
-
Wales
-
Cardiff, Wales, United Kingdom, CF14 4XN
- Recruiting
- University Hospital of Wales
-
Contact:
- Contact Person
- Phone Number: 44-29-2074-7747
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- Diagnosis of non-muscle invasive bladder cancer
Recurrent disease after undergoing induction or maintenance therapy with bacillus Calmette-Guérin (BCG), meeting any 1 of the following criteria:
- Stage Ta or T1 disease (grade 2 or 3)
- Carcinoma in situ with stage Ta or T1 disease (grade 1, 2, or 3)
- Carcinoma in situ alone
- Has undergone a second resection of all T1 disease to exclude muscle invasive disease
- No urothelial cell carcinoma (UCC) ≥ T2
- No recurrence of grade 1 UCC following BCG induction therapy
- No UCC involving the prostatic urethra or upper urinary tract
PATIENT CHARACTERISTICS:
- WHO performance status 0-4
- WBC ≥ 3.0 x 10^9/L
- Absolute neutrophil count ≥ 1.5 x 10^9/L
- Hemoglobin ≥ 10 g/dL
- Platelet count ≥ 100 x 10^9/L
- Serum creatinine < 1.5 times upper limit of normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Normal kidneys and ureters on imaging CT scan within the past 12 months
- Available for long-term follow-up with a life expectancy of the duration of the trial
- Must be fit and willing to undergo a full or partial cystectomy
- No known or suspected reduced bladder capacity (< 250 mL)
- No significant bleeding disorder
- No other malignancy within the past 5 years except nonmelanomatous skin cancer cured by excision, adequately treated carcinoma in situ of the cervix, or DCIS/LCIS of the breast
- No known allergy to mitomycin or bacillus Calmette-Guérin (BCG), or previously withdrawn from BCG treatment due to a related adverse event (e.g., systemic infection)
- No active or intractable urinary tract infection
- No urethral stricture or any situation impeding the insertion of a 20F catheter
- No bladder diverticula > 1 cm
- No significant urinary incontinence
- No concurrent implanted electronic devices (e.g., cardiac pacemakers) or metallic implants within the pelvis, lower torso, spine, hip, or upper femur
- No immunocompromised state for any reason
PRIOR CONCURRENT THERAPY:
- At least 6 months since prior intravesical chemotherapy, except for single instillation post-transurethral resection
- No prior pelvic irradiation
- No prior hyperthermia in combination with intravesical mitomycin
- Concurrent participation in other studies allowed
- No current or long-term use of corticosteroids
- No concurrent chemotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Disease-free survival time
|
Complete response rate at 3 months in patients with carcinoma in situ
|
Secondary Outcome Measures
Outcome Measure |
---|
Quality of Life
|
Safety and tolerability
|
Cost effectiveness
|
Recurrence-free survival time
|
Progression-free survival time
|
Overall survival time
|
Disease-specific survival time
|
Biomarkers of response to standard and investigational treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: John Kelly, MD, University College London Hospitals
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Urinary Bladder Diseases
- Wounds and Injuries
- Body Temperature Changes
- Heat Stress Disorders
- Urinary Bladder Neoplasms
- Hyperthermia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Alkylating Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Interferons
- Interferon-alpha
- Epirubicin
- Mitomycins
- Mitomycin
Other Study ID Numbers
- CRC-TU-BL3010-HYMN
- CDR0000668528 (Registry Identifier: PDQ (Physician Data Query))
- ISRCTN85785327
- EUDRACT-2008-005428-99
- EU-21015
- UCL-08/0365
- KYOWA-CRC-TU-BL3010-HYMN
- MREC-09/H0717/56
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
Clinical Trials on recombinant interferon alfa
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBladder Cancer | Urethral CancerUnited States
-
Seoul National University HospitalHanyang UniversityRecruitingCoronary Artery Disease | Stable Angina | Acute Myocardial InfarctionKorea, Republic of
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedBreast Cancer | Metastatic CancerUnited States
-
Institute of Hematology & Blood Diseases Hospital...RecruitingEssential ThrombocytopeniaChina
-
Hoffmann-La RocheCompletedRenal Cell Carcinoma | Chronic Myelogenous Leukemia | Malignant MelanomaCanada, India, Bulgaria, Russian Federation, Spain, South Africa, Slovakia
-
Institute of Hematology & Blood Diseases Hospital...RecruitingEssential ThrombocytopeniaChina
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI); NCIC Clinical Trials Group; Children's Oncology... and other collaboratorsActive, not recruitingMelanoma (Skin)United States, Canada, Australia, South Africa
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)SuspendedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
Institute of Cancer Research, United KingdomCompletedMelanoma (Skin)United Kingdom